Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

272,475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, Lopez-Corral L, Ries I, Bücklein VL, Mohty R, Dreyling M, Baluch A, Shah B, Locke FL, Hess G, Barba P, Bachy E, Lin Y, Subklewe M, Jain MD. Rejeski K, et al. Among authors: wang y. Am J Hematol. 2023 Nov;98(11):1699-1710. doi: 10.1002/ajh.27056. Epub 2023 Aug 16. Am J Hematol. 2023. PMID: 37584447
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel.
Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Braksick SA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. Wudhikarn K, et al. Among authors: wang y. Am J Hematol. 2021 Nov 1;96(11):E427-E430. doi: 10.1002/ajh.26330. Epub 2021 Sep 7. Am J Hematol. 2021. PMID: 34424554 Free article. No abstract available.
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J. Kraft RM, et al. Among authors: wang y. Hematol Oncol. 2021 Dec;39(5):658-663. doi: 10.1002/hon.2919. Epub 2021 Aug 28. Hematol Oncol. 2021. PMID: 34453851
Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
Saifi O, Breen WG, Lester SC, Rule WG, Stish B, Rosenthal A, Munoz J, Herchko SM, Murthy HS, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Wang Y, Khurana A, Bisneto JCV, Johnston PB, Ansell SM, Iqbal M, Tun H, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Saifi O, et al. Among authors: wang y. Radiother Oncol. 2022 Jan;166:171-179. doi: 10.1016/j.radonc.2021.11.031. Epub 2021 Dec 7. Radiother Oncol. 2022. PMID: 34890736 Free article.
Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.
Breen WG, Hathcock MA, Young JR, Kowalchuk RO, Bansal R, Khurana A, Bennani NN, Paludo J, Villasboas Bisneto JC, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y. Breen WG, et al. Among authors: wang y. J Hematol Oncol. 2022 Mar 26;15(1):36. doi: 10.1186/s13045-022-01256-w. J Hematol Oncol. 2022. PMID: 35346315 Free PMC article.
Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma.
Bansal R, Novo M, Al Saleh AS, Guerrico AG, Zhang H, Shao Z, Babadi E, Martinez KE, McCoy GA, Hathcock MA, Khurana A, Bennani NN, Paludo J, Wang Y, Ansell SM, Johnston PB, Villasboas JC, Lin Y. Bansal R, et al. Among authors: wang y. Am J Hematol. 2022 Jul;97(7):E241-E244. doi: 10.1002/ajh.26561. Epub 2022 Apr 14. Am J Hematol. 2022. PMID: 35385152 Free article. No abstract available.
Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J, Wang Y, Jain P, Wang M. Muñoz J, et al. Among authors: wang y, wang m. Ther Adv Hematol. 2022 May 27;13:20406207221093980. doi: 10.1177/20406207221093980. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35651781 Free PMC article. Review.
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jiménez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martínez-López J, Wang Y, Link BK. Salles G, et al. Among authors: wang y. Blood Adv. 2022 Nov 22;6(22):5835-5843. doi: 10.1182/bloodadvances.2022008150. Blood Adv. 2022. PMID: 35973192 Free PMC article. Clinical Trial.
272,475 results
You have reached the last available page of results. Please see the User Guide for more information.